rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Metaanalysis results showed no significant association between C3435T polymorphism and pediatric ALL risk (TT vs. CC: odds ratio [OR] = 1.20, 95% confidence interval [CI] = 0.95-1.52; CT vs. CC: OR = 1.00, 95% CI = 0.82-1.23; the dominant model: OR = 1.07, 95% CI = 0.89-1.29; the recessive model: OR = 1.17, 95% CI = 0.84-1.62).
|
28845766 |
2017 |
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
C3435T and C1236T MDR1 polymorphism are significantly associated with the high-risk group (OR=2.6, 95%CI=1.164-5.808; P=0.028 and OR=2.231, 95%CI=1.068-4.659; p=0.047, respectively), indicating that both may be candidates for molecular markers in the high-risk group of ALL.
|
25854371 |
2015 |
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This meta-analysis suggests there was no association between MDR1 C3435T polymorphism and children ALL risk in overall populations, but significant association with an increased risk in Asians.
|
25661341 |
2015 |
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
There were no association in distribution of genotypes of MDR-1 C3435T polymorphism and the risk of ALL.
|
23244145 |
2012 |
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To determine the influence of the MDR1 C3435T polymorphism on the development of childhood acute lymphoblastic leukemia (ALL), we studied 107 children with ALL and 111 healthy subjects.
|
19317599 |
2008 |
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Overall, the SNPs considered individually or within haplotypes (C1236T-G2677T/A-C3435T) were not significantly associated with childhood ALL.
|
17548681 |
2007 |
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The frequency of the T/T genotype of the 3435C>T was also significantly higher in ALL (29/118 versus 10/96, p=0.006).
|
17568669 |
2007 |
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In a matched case-control study, we investigated the associations between CNS relapse in childhood ALL and the presence of phenotypically relevant single nucleotide polymorphisms within the GSTP1 (codon 105 and 114) and MDR1 genes (ABCB1; coding for Pgp; exon 26, C3435T).
|
15717687 |
2005 |
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the results of the present study provide evidence that C3435T MDR1 polymorphism may involve both the susceptibility to and the clinical outcome of childhood ALL.
|
15059065 |
2004 |
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, we do not have reason to assume that the C3435T SNP contributes to drug resistance of ALL and prognosis of ALL patients.
|
12851703 |
2003 |
rs1128503
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The present meta-analysis found no evidence for ABCB1 C3435T and C1236T polymorphisms as risk factors for pediatric ALL.
|
28845766 |
2017 |
rs1128503
|
|
|
0.030 |
GeneticVariation |
BEFREE |
C3435T and C1236T MDR1 polymorphism are significantly associated with the high-risk group (OR=2.6, 95%CI=1.164-5.808; P=0.028 and OR=2.231, 95%CI=1.068-4.659; p=0.047, respectively), indicating that both may be candidates for molecular markers in the high-risk group of ALL.
|
25854371 |
2015 |
rs1128503
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Overall, the SNPs considered individually or within haplotypes (C1236T-G2677T/A-C3435T) were not significantly associated with childhood ALL.
|
17548681 |
2007 |
rs2229109
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, there is a statistically significant association between ABCB1 polymorphisms, efficacy and toxicity in the treatment of ALL, and ABCB1 1199G>A may be a new possible predictive marker for outcome in childhood ALL.
|
25582575 |
2015 |
rs200378616
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Sixteen single nucleotide polymorphisms (SNPs) (CYP3A4*1B A>G, CYP3A5*3 G>A, GSTP1 313 A>G, GSTM1 deletion, GSTT1 deletion, MDR1 exon 21 G>T/A, MDR1 exon 26 C>T, MTHFR 677 C>T, MTHFR 1298 A>C, NR3C1 1088 A>G, RFC 80 G>A, TPMT 238 G>C, TPMT 460 G>A, TPMT 719 A>G, VDR intron 8 G>A, VDR FokI T>C) that have been implicated in the pharmacogenetics of ALL therapy were analyzed by TotalPlex amplification and SNP genotyping.
|
18385010 |
2008 |
rs979090956
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Sixteen single nucleotide polymorphisms (SNPs) (CYP3A4*1B A>G, CYP3A5*3 G>A, GSTP1 313 A>G, GSTM1 deletion, GSTT1 deletion, MDR1 exon 21 G>T/A, MDR1 exon 26 C>T, MTHFR 677 C>T, MTHFR 1298 A>C, NR3C1 1088 A>G, RFC 80 G>A, TPMT 238 G>C, TPMT 460 G>A, TPMT 719 A>G, VDR intron 8 G>A, VDR FokI T>C) that have been implicated in the pharmacogenetics of ALL therapy were analyzed by TotalPlex amplification and SNP genotyping.
|
18385010 |
2008 |
rs1164376164
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Buccal cell DNA from ALL cases (n = 294) and controls (n = 369) individually matched on gender, date of birth, Hispanic status, and maternal race were whole genome amplified and genotyped for four MDR1 SNPs, T-129C (rs3213619), C1236T (rs1128503), G2677T/A (rs2032582), and C3435T (rs1045642).
|
17548681 |
2007 |
rs2032582
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Overall, the SNPs considered individually or within haplotypes (C1236T-G2677T/A-C3435T) were not significantly associated with childhood ALL.
|
17548681 |
2007 |
rs3213619
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Buccal cell DNA from ALL cases (n = 294) and controls (n = 369) individually matched on gender, date of birth, Hispanic status, and maternal race were whole genome amplified and genotyped for four MDR1 SNPs, T-129C (rs3213619), C1236T (rs1128503), G2677T/A (rs2032582), and C3435T (rs1045642).
|
17548681 |
2007 |